PRISM MEDICO AND PHARMACY LTD. - 512217 - Board Meeting Outcome for Outcome Of Board Meeting.
Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith the outcome of meeting of the Board of Directors held today (i.e. 20th July, 2023) which commenced at 11:30 A.M. and concluded at 01:00 P.M. You are requested to kindly take the same on record and oblige. PRISM MEDICO AND PHARMACY LTD. - 512217 - Investor Complaints As Per Regulation 13(3) Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations, 2015.
With reference to the captioned subject please find the attached herewith a report on investor complaints for the quarter ended 30th June, 2023. You are requested to kindly take the same on your record and acknowledge receipt. PRISM MEDICO AND PHARMACY LTD. - 512217 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 we hereby furnish a copy of compliance certificate issued by the RTA. You are requested to kindly take the same on your record and acknowledge receipt. PRISM MEDICO AND PHARMACY LTD. - 512217 - Disclosures under Reg. 29(1) & 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) & 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ramit Walia & Charanjit Singh Bhatia PRISM MEDICO AND PHARMACY LTD. - 512217 - Disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ramit Valia PRISM MEDICO AND PHARMACY LTD. - 512217 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Charanjit Singh Bhatia PRISM MEDICO AND PHARMACY LTD. - 512217 - Compliance-57 (5) : intimation after the end of quarter
Pursuant to Regulation 57(5) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (LODR), we hereby confirm that the company has not issued any non-convertible securities. Therefore, there were no interest/dividend/principal obligations which were due for payment during the quarter 01st April, 2023 to 30th June, 2023. You are requested to kindly take the same on your record and acknowledge the receipt. PRISM MEDICO AND PHARMACY LTD. - 512217 - Closure of Trading Window
Pursuant to code of conduct to regulate, monitor and report trading by the insiders (Code) and applicable SEBI Regulations, we would like to inform you that trading window for dealing in securities of the company by the insiders stands closed from 01st July, 2023 and will be re-opened 48 hours after the declaration of financial results for the quarter ended 30th June , 2023 to the Stock Exchange. PRISM MEDICO AND PHARMACY LTD. - 512217 - Compliance-57 (4) : Prior intimation to the beginning of the quarter
Pursuant to Regulation 57(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (LODR), it is informed that the company has not issued any non-convertible securities of the company for which interest/dividend/principal amount shall be payable during the ensuing quarter i.e. from 01st July, 2023 to 30th September, 2023. You are requested to kindly take the same on your record and acknowledge receipt. PRISM MEDICO AND PHARMACY LTD. - 512217 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Galaxy Vitacare Pvt Ltd, Paramjeet Kaurand Jasjot Singh, Ramit Walia